Re then expressed as imply SE. One way ANOVA followed by post-hoc Dunnett’s test was applied for many comparisons, though Student’s t test was employed for comparing the two classes of data shown in figures. A P 0.05 value was considered statistically significant. The half Inhibitory Concentration (IC50) of metformin was calculated on cell count, MTS and thymidine-incorporation dose-response curves employing Origin application 6.1 version (OriginLab Corporation, Northampton, MA).Perri G, Terzolo M. Influence on the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics. 2013; 23:29300. four. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and lowered threat of cancer in diabetic individuals. BMJ. 2005; 330:1304. five. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic critique and metaanalysis. Cancer Prev Res (Phila). 2010; three:14511. six. Johnson JA, Bowker SL. Intensive glycaemic manage and cancer threat in variety 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011; 54:251. 7. Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, Rotella CM, Mannucci E. Metformin and cancer occurrence in insulin-treated form two diabetic individuals. Diabetes Care. 2011; 34:1291. eight. Pollak M. Prospective applications for biguanides in oncology. J Clin Invest. 2013; 123:369300. 9. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and therapy. Trends Endocrinol Metab. 2013; 24:4690. 10. Karnevi E, Said K, Andersson R, Rosendahl AH. Metformin-mediated development inhibition involves suppression with the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 2013; 13:235. 11. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, Ercolino T, Galli A, Serio M, Mannelli M, Luconi M. Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering using the IGF-IR intracellular signaling. PPAR Res. 2008; 2008:904041. 12. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP, Lalli E. Regulation of insulin-like development factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumours. Cancer Res. 2010; 70:46665. 13. Doghman M, Lalli E. Efficacy from the novel dual PI3-kinase/ mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.Price of 3-Bromo-1-naphthoic acid Mol Cell Endocrinol. 2012; 364:101. 14. De Martino MC, Feelders RA, de Herder WW, van Koetsveld PM, Dogan F, Janssen JA, Waaijers AM, Pivonello C, Lamberts SW, Colao A, de Krijger RR, Pivonello R, Hofland LJ.42225-04-7 Chemscene Characterization of your mTOR pathway in human typical adrenal and adrenocortical tumours.PMID:26644518 Endocr Relat Cancer. 2014; 21:6013. 15. Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, Ercolino T, Serio M, Orlando C, et al. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study inside a xenograft mouse model. Endocr Relat Cancer. 2010; 17:1697. 49646 OncotargetACKNOWLEDGMENTsWe thank Prof. Paola Chiarugi, Dr. Giuseppe Castronovo, Dr. Tommaso Mello and Dr. NiccolBartalucci (University of Florence) for providing the antiphospho AMPK, anti-Caspase three, anti-mTOR and anti-Bclxl antibodies, respectively.CONFLICTs OF INTEREsTThe authors declare no conflicts of interest R. Armignacco, G. C.
